stock ticker for SENS

[wp-rss-aggregator feeds=”sens”]

Updates:

Form SC 13D/A, 3 FEB 2021: http://archive.fast-edgar.com/20210203/AQZ2F222H222KTZ2222W2ZZEJ9QKJ22SB232/

Form 8-K, 26 JAN 2021: http://archive.fast-edgar.com/20210126/A3BZA22C8222JTZZ272H2ZZZ6PVCZ2V2ZB32/

Senseonics Holdings Announces $50.0 Million Bought Deal Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) (Senseonics or the Company), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 25,974,026 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 3,896,103 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The gross proceeds of the offering are expected to be approximately $50.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses and excluding the exercise of the underwriters option to purchase additional shares. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital, product development focused on working to complete the 365-day Eversense system, capital expenditures and supporting the collaboration with Ascensia Diabetes Care.
Source: https://www.businesswire.com/news/home/20210121005965/en/

Leave a Reply